Olfactory Neuroblastoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-01-10
Clinical Trial Update: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma [Phase 2]
A Phase II study of Rivoceranib for recurrent or metastatic olfactory neuroblastoma has been withdrawn from the registry; no results are rep…